Olema Pharmaceuticals, Inc.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
OLMA$7.27-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(unaudited)
(Amounts in thousands)
| Three Months Ended March 31, | ||||
|---|---|---|---|---|
| 2025 · 2024 | ||||
| Cash flows from operating activities: | ||||
| Net loss | $ | (30,389) | $ | (30,970) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation and amortization expense | 128 | 88 | ||
| Non-cash lease expense | 287 | 288 | ||
| Non-cash interest income on marketable securities | (2,101) | (2,355) | ||
| Stock-based compensation expense, including employee stock purchase plan expense | 4,378 | 4,909 | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other current assets | 549 | 1,593 | ||
| Other assets and long-term deposits | (965) | (1,343) | ||
| Accounts payable | (4,309) | 4,958 | ||
| Other current liabilities | (11,248) | (404) | ||
| Operating lease liabilities | (309) | (260) | ||
| Net cash used in operating activities | (43,979) | (23,496) | ||
| Cash flows from investing activities: | ||||
| Purchase of equipment | — | (153) | ||
| Maturities of marketable securities | 97,772 | 56,100 | ||
| Purchases of marketable securities | (142,855) | (76,091) | ||
| Net cash used in investing activities | (45,083) | (20,144) | ||
| Cash flows from financing activities: | ||||
| Issuance of shares under at-the-market offering, net of issuance costs of $166 | — | 7,901 | ||
| Issuance costs for shares issued under private placement | (14) | — | ||
| Proceeds from exercise of stock options | 236 | 920 | ||
| Net cash provided by financing activities | 222 | 8,821 | ||
| Net decrease in cash and cash equivalents | (88,840) | (34,819) | ||
| Cash and cash equivalents at beginning of period | 139,480 | 68,539 | ||
| Cash and cash equivalents at end of period | $ | 50,640 | $ | 33,720 |
| Supplemental disclosure of non-cash financing activity | ||||
| Exchange of common stock for pre-funded warrants | $ | 29,379 | $ | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.